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Abstract
Background: Although amnestic mild cognitive impairment (aMCI) is generally considered to be a prodromal stage
of Alzheimer’s disease, patients with aMCI show heterogeneous patterns of progression. Moreover, there are few
studies investigating data-driven cognitive trajectory in aMCI. We therefore classified patients with aMCI based on
their cognitive trajectory, measured by clinical dementia rating sum of boxes (CDR-SOB). Then, we compared the
clinical and neuroimaging features among groups classified by cognitive trajectory.
Methods: We retrospectively recruited 278 patients with aMCI who underwent three or more timepoints of
neuropsychological testing. They also had magnetic resonance imaging (MRI) including structured three-
dimensional volume images. Cortical thickness was measured using surface-based methods. We performed
trajectory analyses to classify our aMCI patients according to their progression and investigate their cognitive
trajectory using CDR-SOB.
Results: Trajectory analyses showed that patients with aMCI were divided into three groups: stable (61.8%), slow
decliner (31.7%), and fast decliner (6.5%). Changes throughout a mean follow-up duration of 3.7 years in the CDR-SOB
for the subgroups of stable/slow/fast decliners were 1.3-, 6.4-, and 12-point increases, respectively. Decliners were older
and carried apolipoprotein E4 (APOE4) genotypes more frequently than stable patients. Compared with the stable
group, decliners showed a higher frequency of aMCI patients with both visual and verbal memory dysfunction, late
stage aMCI, and multiple domain dysfunction. In addition, compared with the stable group, the slow decliners showed
cortical thinning predominantly in bilateral parietotemporal areas, while the fast decliners showed cortical thinning
predominantly in bilateral frontotemporal areas. Both decliner groups showed worse cognitive function in attention,
language, visuospatial, memory, and frontal/executive domains than the stable group.
Conclusions: Our data-driven trajectory analysis provides new insights into heterogeneous cognitive trajectories of aMCI
and further suggests that baseline clinical and neuroimaging profiles might predict aMCI patients with poor prognosis.
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Background
Mild cognitive impairment (MCI) refers to an intermedi-
ate state between normal aging and dementia with cog-
nitive dysfunction but no functional impairment. In
particular, MCI with memory deficits defined as amnes-
tic MCI (aMCI) is considered to be a prodromal state of
Alzheimer’s disease (AD) [1]. However, the clinical out-
comes of aMCI patients are heterogeneous, as some pa-
tients quickly progress to AD dementia while others
remain stable or even revert to normal cognition [2–4].
Identification of poor prognostic factors would therefore
be important for patient counseling, risk stratification,
and management.
Previous studies have shown that several factors affect
the frequency of conversion to dementia or progression
of aMCI [2, 5, 6]. These studies have shown that aMCI
is more likely to progress in patients with brain atrophy,
with evidence of amyloid deposition (measured using
positron emission tomography (PET)), and carriage of
the apolipoprotein E4 (APOE4) allele [7, 8]. Previous
studies from our group also showed that the progression
of aMCI to dementia depended on the modality and se-
verity of involved memory dysfunction, and the multipli-
city of impaired cognitive domains [9–13]. However,
these studies were based on hypothesis-driven analysis,
that is researchers classified participants into several
subgroups according to their hypothesis. In contrast, the
use of trajectory analysis is a data-driven classification
approach. It is designed to identify clusters of individuals
who have followed a similar trajectory on longitudinal
performance. It would thus enable identification,
summarization, and communication of complex prog-
nostic factors in longitudinal data [14]. It would further
provide distinct longitudinal trajectories by complex
prognostic profiles as disease progresses over time. In-
deed, a recent study from our group suggested that tra-
jectory analysis is useful to identify prognostic profiles in
patients with non-amnestic MCI [15].
In the present study, we applied trajectory analysis
in aMCI patients to better predict their heterogeneous
prognosis. First, we identified several distinct cogni-
tive trajectories based on longitudinal performance as
measured by the clinical dementia rating sum of
boxes (CDR-SOB) score. Second, we tested our hy-
pothesis that subgroups classified by trajectory ana-
lysis may reflect subgroups with known prognostic
factors including the modality and severity of involved
memory dysfunction, and the multiplicity of impaired
cognitive domains suggested by previous studies based
on hypothesis-driven analysis [12, 13, 16, 17]. Finally,
we compared clinical features, genotypes, and cortical
thickness among subgroups classified by trajectory
analysis and identified which profiles might predict
aMCI with poor prognosis.
Methods
Participants
We retrospectively recruited 278 patients who were clin-
ically diagnosed with aMCI and underwent more than
three timepoints of neuropsychological tests at Samsung
Medical Center between March 2001 and May 2013. All
patients fulfilled the Petersen’s criteria [18] for MCI with
modifications: 1) subjective memory complaint by the
patient or his/her caregiver; 2) normal general cognitive
function above −1.0 standard deviation (SD) on the
Korean version of the Mini-Mental State Examination
(K-MMSE); 3) normal activities of daily living (ADL) as
judged by both an interview with a clinician and the
standardized ADL scale previously described [9]; 4) ob-
jective memory decline lower than −1.0 SD on the Seoul
Verbal Learning test (SVLT) and Rey-Osterrieth
Complex Figure Test (RCFT), which represent verbal
memory and visual memory, respectively; and 5) not de-
mented. No patient had a family history suggesting auto-
somal dominant disease. We excluded participants if
they had a history of a neurological disorder, major de-
pression disorder or other psychiatric disorders, sub-
stance abuse, or head trauma with loss of consciousness.
Possible secondary causes for cognitive deficits were
accounted for by acquiring a physiological test panel in-
cluding complete blood count, blood chemistry, vitamin
B12, folate, syphilis serology, and thyroid function. We
excluded patients with other structural lesions detected
on brain magnetic resonance imaging (MRI), including
territorial infarction, intracranial hemorrhage, brain
tumor, hydrocephalus, or severe white matter hyperin-
tensity (WMH).
We obtained written informed consent from each par-
ticipant, and the institutional review board of the Sam-
sung Medical Center approved the study protocol.
Neuropsychological tests
All patients underwent neuropsychological tests using the
Seoul Neuropsychological Screening Battery (SNSB). This
battery includes quantitative tests, including digit span
(forward and backward), the Korean version of the Boston
Naming Test (K-BNT), the RCFT (copying, immediate,
and 20-min delayed recall, and recognition), the SVLT
(three learning-free recall trials of 12 words, a 20-min de-
layed recall trial for these 12 items, and a recognition test),
the phonemic and semantic Controlled Oral Word
Association Test (COWAT), Stroop Test (word and color
reading of 112 items during a 2-min period), the
K-MMSE, and the clinical dementia rating (CDR) scale.
Classification of aMCI patients
We classified patients with aMCI into several subgroups
by the modality and severity of involved memory dysfunc-
tion, and the multiplicity of involved cognitive domains,
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based on previous studies from our group [9–13]. We
classified patients with aMCI into three subgroups
according to the modality of involved memory dys-
function: patients with only visual memory dysfunc-
tion (Visual-aMCI), those with only verbal memory
dysfunction (Verbal-aMCI), and those with both visual
and verbal memory dysfunction (Both-aMCI). Therefore,
Verbal-, Visual-, and Both-aMCI patients have scores
lower than −1.0 SD of age- and education-matched norms
in the delayed recall item scores of verbal memory test,
visual memory test, and both verbal and visual memory
tests, respectively. We also classified patients with aMCI
according to the severity of memory dysfunction. If pa-
tients with aMCI had scores on delayed recall tests be-
tween 1.0 and 1.5 SD below norms, they were considered
to have mild memory dysfunction and classified as early
stage aMCI (E-aMCI); if patients had scores lower than
1.5 SD below norms in delayed recall item scores of either
verbal memory or verbal memory tests, they were consid-
ered to have severe memory dysfunction and classified as
late stage aMCI (L-aMCI). Finally, patients with aMCI
were classified according to the multiplicity of involved
cognitive domains. Patients with isolated memory dys-
function were assigned as single-domain aMCI (Single--
aMCI), and patients having memory impairment plus
other cognitive deficits, such as language and visuospatial
dysfunction, were assigned as multiple-domain aMCI
(Multiple-aMCI).
MRI techniques
Standardized T2, three-dimensional (3D) T1 turbo field
echo, 3D fluid-attenuated inversion recovery (FLAIR), and
DTI images were acquired from all applicable subjects at
the Samsung Medical Center using the same 3.0-T MRI
scanner (Philips 3.0 T Achieva). Detailed imaging parame-
ters are described in Additional file 1 (Text S1).
Cortical thickness measurement image processing
T1-weighted MR images were automatically processed
using the standard Montreal Neurological Institute
image processing software (CIVET) to measure cortical
thickness. The software has been well validated and ex-
tensively described elsewhere including aging/atrophied
brain studies [19–23]. Detailed imaging parameters are
described in Additional file 1 (Text S2).
APOE genotyping
Genomic DNA was extracted from peripheral blood leu-
kocytes using the Wizard Genomic DNA Purification kit
following the manufacturer’s instructions (Promega,
Madison, WI, USA). Two single nucleotide polymor-
phisms (rs429358 for codon 112 and rs7412 for codon
158) in the APOE gene were genotyped using Taq-
ManSNP Genotyping Assays (Applied Biosystems,
Foster City, CA, USA) on a 7500 Fast Real-Time PCR
System (Applied Biosystems) following the manufac-
turer’s instructions.
Follow-up evaluations
Of the 278 patients who underwent baseline and two or
more follow-up neuropsychological evaluations, 230 com-
pleted the first follow-up 1 year after the baseline assess-
ment. One hundred and eighty-seven patients completed
two consecutive follow-up neuropsychological evaluations
annually. One hundred and forty-seven patients completed
the follow-up more than three times. Seventy-four patients
completed the follow-up more than four times. Forty-four
patients completed the follow-up more than five times.
Fifteen patients completed the follow-up more than six
times. Five patients completed the follow-up more than
seven times. Three patients completed the follow-up more
than eight times (Additional file 1: Table S1).
Conversion to dementia
We diagnosed dementia using criteria from the DSM-IV,
which requires cognitive impairment detected by neuro-
psychological tests. Such cognitive impairment should
be sufficient to interfere with independence in ADL. We
did not use the MMSE or CDR-SOB scores as a diagnos-
tic tool for dementia.
Statistical analysis
We used group-based trajectory modeling to identify
distinct cognitive trajectories. Group-based trajectory
modeling fits a discrete, semiparametric mixture model
to longitudinal data using maximum likelihood methods
to estimate membership probabilities for multiple trajec-
tories [24]. This approach groups individuals with the
same cognitive progression trajectory in the same class.
To investigate the cognitive trajectory, CDR-SOB was
used. The Bayesian information criterion (BIC) was used
to select the number of trajectories that best fit the data.
Demographic data were analyzed using one-way ana-
lysis of variance (ANOVA) for continuous variables and
chi-square tests for categorical variables. To investigate
the distribution of aMCI subtype, we performed
chi-square tests. Furthermore, post-hoc analyses were
performed using the Bonferroni’s correction for multiple
comparisons. To compare baseline cognitive function,
we performed an analysis of covariance (ANCOVA), in-
cluding age, gender, and years of education as covariates.
To investigate differences in the baseline mean cortical
thickness, we performed an ANCOVA, including age,
gender, years of education, and intracranial volume
(ICV) as covariates.
Diffusion smoothing with a full-width half-maximum of
20mm was used to blur each cortical thickness map, lead-
ing to an increased signal-to-noise ratio and an increased
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statistical power [20]. To evaluate the topography of cor-
tical thickness related to gait disturbances, multiple linear
regression analysis was performed on a vertex-by-vertex
basis using the Surfstat package (http://www.math.mc-
gill.ca/keith/surfstat) after controlling for age, gender, years
of education, and ICV. The cortical surface model con-
tained 81,924 vertices; thus, correction for multiple com-
parisons was accomplished using the random field theory
method [25] at a corrected probability value of 0.05. Tra-
jectory analyses were conducted with SAS using Proc Traj
procedure [24]. All other analyses were performed using
PASW (version 18.0; SPSS, Chicago, IL, USA).
Results
Groups classified according to cognitive trajectories
Detailed demographic and clinical characteristics of par-
ticipants at baseline are presented in Table 1. To define
the cognitive trajectories we evaluated models with one
to five groups. According to the BIC values, the
three-group model was found to be the best. The trajec-
tories are illustrated in Fig. 1. Among 278 patients, 142
(51.0%), 105 patients (37.8%), and 31 patients (11.2%)
were classified into the “stable”, “slow decliner”, and
“fast decliner” trajectory groups, respectively. CDR-SOB
of the stable/slow decliner/fast decliner groups were
1.01/1.61/1.98 at baseline, 1.17/3.63/8.25 at 3 years after
baseline, and 1.63/5.00/10.60 at 5 years after baseline, re-
spectively (Additional file 1: Table S2).
The mean age of patients in the fast decliner group
was higher (74.5 ± 6.2, p = 0.006) than in the stable
group (70.0 ± 7.0) (Table 1). No differences were found
in gender and education among the three groups. There
were also no differences in the frequency of vascular risk
factors among the three groups. Patients with the APOE
e4 allele were more frequent in the slow decliner group
(48.4%) than in the stable group (28.7%).
With a mean follow-up duration of 3.7 years, 124 (44.6%)
aMCI patients converted to dementia and 31 (11.2%) aMCI
patients reverted to a cognitively normal state (Table 1). All
fast decliners and 83 (79.0%) slow decliners converted to
dementia while only 10 (7.0%) of the stable group converted
to dementia. The reverters were all in the stable group.
Distribution of aMCI subgroups
The distributions of aMCI subgroups are shown in Fig. 2
and Additional file 1 (Table S3). There were differences in
the distribution of aMCI subgroups among the three
groups. Post-hoc analyses revealed that, compared with
stable aMCI, slow decliners showed a higher frequency of
Both-aMCI than Visual-aMCI (p < 0.001) or Verbal-aMCI
(p = 0.009) and a higher frequency of L-aMCI than
E-aMCI (p < 0.001). Compared with the stable group, fast
decliners showed a higher frequency of Both-aMCI than
that of Visual-aMCI (p < 0.027), a higher frequency of
L-aMCI than that of E-aMCI (p < 0.001) and a higher
frequency of Multiple-aMCI than that of Single-aMCI
(p < 0.001). Compared with slow decliners, fast de-
cliners also showed a higher frequency of Multiple-
aMCI than that of Single-aMCI (p = 0.045).
Baseline neuropsychological features according to
cognitive trajectories group
Compared with the stable group, the fast decliners
showed lower baseline scores on K-BNT, RCFT copy,
Table 1 Demographics and clinical characteristics
Total (n = 278) Stable (n = 142) Slow decliner (n = 105) Fast decliner (n = 31) p valuea
Age, years 70.9 ± 7.12 70.0 ± 6.97 71.1 ± 7.29 74.5 ± 6.17b 0.006
Gender, female (%) 166 (59.7) 83 (58.5) 62 (59.0) 21 (67.7) 0.624
Education, year 11.5 ± 4.90 11.5 ± 4.99 11.4 ± 4.91 11.9 ± 4.56 0.896
Vascular risk factor (%)
Hypertension 109/244(44.6%) 52/116 (44.9%) 43/97 (44.4%) 14/31 (45.2%) 0.891
Diabetes mellitus 76/244 (31.1%) 34/116 (29.3%) 32/97 (33.0%) 10/31 (32.3%) 0.475
Hyperlipidemia 64/244 (26.2%) 33/116 (28.5%) 21/97 (21.6%) 10/31 (32.3%) 0.508
Cardiac disease 50/244 (20.5%) 21/116 (18.1%) 23/97 (23.7%) 6/31 (19.3%) 0.551
Previous stroke 8/243 (3.3%) 6/115 (5.2%) 2/97 (2.1%) 0/31 (0%) 0.374
APOE genotype (%)
APOE e2 carrier 21 (8.4) 15 (11.6) 5 (5.5) 1 (3.6) 0.427
APOE e4 carrier 93 (37.3) 37 (28.7) 44 (48.4)b 11 (39.2) 0.025
Conversion to dementia (%) 124 (44.6) 10 (7.0) 83 (79.0) 31 (100) < 0.0001
Reversion to normal (%) 31 (11.2) 31 (21.8) 0 (0) 0 (0) < 0.0001
APOE apolipoprotein E
aAnalysis of covariance (ANCOVA) or chi-square test was performed
bSignificant difference compared with the stable group, defined as p < 0.05 from post-hoc analysis using Bonferroni’s correction
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SVLT immediate and delayed recall, RCFT delayed re-
call, COWAT animal and supermarket, Stroop color
reading, and K-MMSE (Table 2). Compared with the
stable group, the slow decliners showed significantly
lower scores on K-BNT, SVLT delayed recall, RCFT
delayed recall, COWAT animal and supermarket,
Stroop color reading, and K-MMSE. Although there
was no statistically significant difference, compared
with the stable group the fast decliners showed a
lower score on the geriatric depression scale (GDeS)
(p = 0.92). There were no differences in scores of
neuropsychological tests between the fast decliners
and the slow decliners, except for CDR-SOB.
Baseline cortical thickness according to cognitive
trajectory group
At baseline, the mean cortical thickness of the fast
decliners was lower than the stable aMCI group in
the frontal, temporal, and parietal regions, and the
mean cortical thickness of the slow decliners was
lower than the stable group for all lobes
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Fast decliner (N = 31, 11.2%)
Slow decliner (N = 105, 37.8%)
Stable (N = 142, 51.0%)
Fig. 1 Trajectories of clinical dementia rating sum of boxes (CDR-SOB) of amnestic mild cognitive impairment
Fig. 2 Distribution of amnestic mild cognitive impairment subgroups. aMCI amnestic mild cognitive impairment, Both-aMCI aMCI with both verbal and
visual memory impairment, Early-stage aMCI aMCI with delayed recall item scores between 1.0–1.5 SD below age- and education-matched norms on
both verbal and visual memory tests, Late-stage aMCI aMCI with delayed recall item scores 1.5 SD below age- and education-matched norms on either
verbal or visual memory tests, Multiple-aMCI aMCI with memory and dysfunction affecting other cognitive domains, Single-aMCI aMCI with memory
deficit alone, Verbal-aMCI aMCI with predominant verbal memory impairment, Visual-aMCI aMCI with predominant visual memory impairment
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Cortical thinning topography at baseline is shown in
Fig. 3. The fast decliners showed more cortical thinning
than the stable group in the bilateral dorsolateral and
medial frontal, lateral temporal, right orbitofrontal, lat-
eral parietal, medial temporal, and lateral occipital re-
gions. The slow decliners showed more cortical thinning
in the bilateral lateral parietal, medial temporal, left
medial frontal, lateral temporal, and right dorsolateral
frontal regions compared with the stable group. The fast
decliners showed more cortical thinning in the right su-
perior temporal gyrus than the slow decliners.
Discussion
In the present study, trajectory analysis of aMCI classi-
fied three distinct cognitive trajectories including stable
aMCI, slow decliners, and fast decliners, which may
reflect subgroups with known prognostic factors sug-
gested by previous studies [9–11]. We also found that,
compared with the stable group, the slow decliners and
the fast decliners showed more extensive cortical thin-
ning in the parietotemporal and frontotemporal regions
at baseline, respectively. In addition, both types of de-
cliners had worse baseline cognition and more domains
of impaired cognition compared with the stable group.
Taken together, our data-driven trajectory analysis pro-
vides new insights into heterogeneous cognitive trajec-
tories of aMCI and further suggest that baseline clinical
and neuroimaging profiles might predict aMCI patients
with poor prognosis.
Our conclusion that the trajectory analysis was useful
for identifying distinct trajectories of stable, slow de-
cliner, and fast decliners is supported by the following
Table 2 Comparison of neuropsychological tests between groups at baseline
Stable (n = 142) Slow decliner (n = 105) Fast decliner (n = 31)
K-MMSE 27.1 ± 2.16ab 24.7 ± 2.98 24.4 ± 2.66
CDR SOB 1.01 ± 0.680ab 1.61 ± 0.766 1.98 ± 0.871c
Attention
Digit span forward 5.8 ± 1.41 5.7 ± 1.52 5.6 ± 1.52
Digit span backward 3.8 ± 1.27 3.5 ± 1.00 3.4 ± 0.89
Language and related abilities
K-BNT 42.7 ± 8.93ab 38.2 ± 9.60 34.6 ± 9.80
Calculation 11.0 ± 1.73 11.0 ± 1.80 11.1 ± 1.20
Ideomotor apraxia 4.6 ± 0.82b 4.4 ± 1.06 4.0 ± 1.37
Visuospatial function
RCFT copy 31.0 ± 4.33b 29.7 ± 6.41 28.2 ± 6.64
Memory
SVLT: immediate recall 16.1 ± 4.12b 14.8 ± 3.87 13.2 ± 3.73
SVLT: delayed recall 3.5 ± 2.31ab 1.3 ± 1.64 1.3 ± 2.29
SVLT: recognition 19.0 ± 2.75a 17.4 ± 2.40 18.3 ± 2.21
RCFT: immediate recall 9.0 ± 5.36 6.9 ± 10.92 6.1 ± 4.26
RCFT: delayed recall 8.6 ± 5.16ab 5.2 ± 3.91 5.0 ± 3.95
RCFT: recognition 18.8 ± 2.15ab 17.6 ± 2.24 17.2 ± 2.26
Frontal/executive function
COWAT animal 13.5 ± 3.82ab 11.6 ± 4.24 10.0 ± 2.20
COWAT supermarket 14.4 ± 5.88ab 11.8 ± 4.72 9.6 ± 3.47
COWAT phonemic 22.4 ± 10.64 21.2 ± 10.90 18.6 ± 7.30
Stroop test: word reading 109.0 ± 8.90 107.1 ± 12.76 108.4 ± 10.71
Stroop test: color reading 73.6 ± 24.28ab 62.9 ± 25.21 52.7 ± 19.93
Geriatric depression scale 12.8 ± 7.25 11.9 ± 7.01 9.2 ± 5.55
Analysis of covariance (ANCOVA) was performed after adjusting for age, gender, and years of education, followed by post-hoc analysis with Bonferroni’s method.
Bonferroni’s correction was also used to correct for multiple neuropsychological tests (defined as p < 0.05)
CDR-SOB clinical dementia rating sum of boxes, COWAT Controlled Oral Word Association Test, K-BNT Korean version of the Boston Naming Test, K-MMSE Korean
version of Mini-Mental State Examination, RCFT Rey-Osterrieth Complex Figure Test, SVLT Seoul Verbal Learning Test,
ap < 0.05 with Bonferroni’s post-hoc analyses comparing the stable group and the slow decliner group
bp < 0.05 with Bonferroni’s post-hoc analyses comparing the stable group and the fast decliner group
cp < 0.05 with Bonferroni’s post-hoc analyses comparing the slow decliner group and the fast decliner group
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observations. First, as we expected, all fast decliners and
most of the slow decliners showed conversion to demen-
tia while none of decliners reverted to cognitively
normal. Second, subgroups classified by the trajectory
analysis reflect subgroups with known prognostic factors
suggested by previous studies based on hypothesis-
driven analysis [2, 9–13, 16, 17, 26, 27], that is previous
studies showed that, depending on the modality and se-
verity of involved memory dysfunction and multiplicity
of involved cognitive domains, some subtypes of aMCI
had more cortical thinning or faster progression than
other subtypes of aMCI [16]: Both-aMCI compared with
Visual-aMCI [10, 12, 26]; L-aMCI compared with
E-aMCI [11, 13, 27]; and Multiple-aMCI compared with
Single-aMCI [2, 9, 17]. Our present study also suggested
similar results, showing that Both-aMCI, L-aMCI, and
Multiple-aMCI were included more frequently in the de-
cliners than the stable group, compared with Visual-
aMCI, E-aMCI, and Single-aMCI, respectively.
One major finding was that, compared with the stable
group, the decliners showed more extensive cortical thin-
ning in the parietotemporal and frontotemporal regions,
respectively. This is consistent with our other finding
showing that, compared with the stable group, the slow
decliners and the fast decliners showed lower scores in
language, memory, and frontal/executive function do-
mains. The present finding is also consistent with our pre-
vious study based on non-amnestic MCI showing that
decliners had decreased cortical thickness compared with
the stable group [15]. These regions are known to be
predominantly affected in AD [28]. Specifically, brain atro-
phy from MCI to AD starts in the medial temporal region
and then spreads to the posterior temporal regions,
followed by parietal regions, and finally to frontal regions
[29, 30]. The temporoparietal involvement of the slow de-
cliners might imply earlier features of AD pathology.
Meanwhile, the fast decliners showed more cortical thin-
ning in regions extending to and including the frontal
lobe. Previous studies reported that frontal involvement
predicted a more rapid progression of cognitive decline in
aMCI [6, 31]. Our findings therefore suggest that the slow
and fast decliners might represent earlier and later stages
of AD-like cortical thinning patterns, respectively.
We also found that the fast decliners showed de-
creased cortical thickness in the right superior temporal
gyrus relative to the slow decliners. When pathologic
changes appear in the superior temporal gyrus, it corre-
sponds to Braak stage V of cortical neurofibrillary path-
ology [32]. This means that the superior temporal gyrus
is one of the areas involved in advanced stage AD. In a
tau-PET study, most MCI patients were assigned to
Braak stage III/IV, while tracer uptake in neocortical
Braak regions (Stage V) was related to structural and
cognitive markers of AD [33]. This suggests that uptake
of the more advanced Braak stage regions might be
more sensitive to the transition from MCI to dementia.
Therefore, thinning of the right superior temporal
gyrus might be associated with rapid progression of
aMCI; however, more evidence is needed to confirm
this result.
Fig. 3 Statistical maps comparing baseline cortical thickness. Localized differences in cortical thickness between stable, slow decliners, and fast
decliners were analyzed with a general linear model on a vertex-by-vertex basis after controlling for age, gender, years of education, and
intracranial volume (defined as p < 0.05). MCI mild cognitive impairment, RFT random field theory
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The strength of the trajectory analysis performed in
this study is the identification of comprehensive clinical
and imaging variables predicting individuals who would
show rapid progression. In the present study, we found
that the clinical and imaging variables such as old age,
APOE4 carrier, decreased cortical thickness, and worse
cognitive impairments discriminated decliners from the
stable group. This finding is consistent with previous
studies showing that older age at diagnosis predicted
more rapid progression of aMCI or conversion to de-
mentia [16, 34]. In addition, the APOE4 gene is the
major genetic risk factor for the conversion of aMCI to
AD [35], likely acting through various mechanisms in-
cluding impaired amyloid clearance. Furthermore, higher
CDR-SOB and decreased cortical thickness in the right
superior temporal gyrus predicted rapid decliners.
Interestingly, the stable group seemed to be different
from the decliner groups. A few (7.0%) in the stable group
converted to dementia with a mean follow-up period of 5
years, and over 20% of those in the stable group reverted
to a cognitively normal state [36]. Considering another
finding that GDeS scores were higher in the stable group
than in decliners, cognitive impairment in the stable group
might be partially related to other causes including de-
pression or anxiety rather than AD. Further studies with
molecular biomarkers are needed.
There are several limitations to our study. First, patients
were selected from a single center, and several patients
withdrew during the follow-up period resulting in a rela-
tively small number of patients therefore limiting the
generalizability of the results. Second, the aMCI diagnosis
was based on clinical phenotype and without pathologic
confirmation, and we therefore could not identify the
pathological underpinnings of the patients included in this
study. Finally, and unexpectedly, 51% of aMCI patients
were classified into the stable aMCI group. The proportion
of stable aMCI patients seems to be higher compared with
previous studies showing a stable aMCI proportion of about
40% [16, 37]. The higher proportion of stable aMCI partici-
pants in our study might be related to selection bias (i.e.,
survival bias in the cohort study). That is, the stable group
has been followed up continuously while decliners were
dropped during the follow-up period. Another potential
possibility is related to the differences in study population
(early stage and late stage of aMCI in our sample compared
with late-stage aMCI in the previous studies) [38].
Conclusions
In the present study, our data-driven trajectory analysis pro-
vides new insights into heterogeneous cognitive trajectories
of aMCI. Our findings clearly suggest that identification of
comprehensive baseline clinical and neuroimaging profiles
from trajectory analysis may help to detect individuals at
greatest risk for dementia and thus inform interventions.
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